MOTRIN IB Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Motrin Ib, and when can generic versions of Motrin Ib launch?
Motrin Ib is a drug marketed by J And J Consumer Inc and is included in one NDA.
The generic ingredient in MOTRIN IB is ibuprofen. There are sixty-four drug master file entries for this compound. Two hundred and thirty-eight suppliers are listed for this compound. Additional details are available on the ibuprofen profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Motrin Ib
A generic version of MOTRIN IB was approved as ibuprofen by STRIDES PHARMA on September 24th, 1986.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for MOTRIN IB?
- What are the global sales for MOTRIN IB?
- What is Average Wholesale Price for MOTRIN IB?
Summary for MOTRIN IB
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 207 |
| Clinical Trials: | 73 |
| Patent Applications: | 4,329 |
| What excipients (inactive ingredients) are in MOTRIN IB? | MOTRIN IB excipients list |
| DailyMed Link: | MOTRIN IB at DailyMed |
Recent Clinical Trials for MOTRIN IB
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Miami | Phase 2 |
| Guangzhou Kangqi Medical Technology Co., LTD | Phase 1 |
| Weill Medical College of Cornell University | Phase 4 |
Pharmacology for MOTRIN IB
| Drug Class | Nonsteroidal Anti-inflammatory Drug |
| Mechanism of Action | Cyclooxygenase Inhibitors |
US Patents and Regulatory Information for MOTRIN IB
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| J And J Consumer Inc | MOTRIN IB | ibuprofen | TABLET;ORAL | 019012-003 | Dec 17, 1990 | OTC | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for MOTRIN IB
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| Recordati Rare Diseases | Pedea | ibuprofen | EMEA/H/C/000549 Treatment of a haemodynamically significant patent ductus arteriosus in preterm newborn infants less than 34 weeks of gestational age. |
Authorised | no | no | no | 2004-07-28 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
